primary human lymphatic endothelial cells hlecs Search Results


human lymphatic endothelial cell line hlecs  (iCell Gene Therapeutics)
90
iCell Gene Therapeutics human lymphatic endothelial cell line hlecs
Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a – c Anlotinib inhibited the proliferation ( a ), migration ( b ), and tubule network formation ( c ) of <t>hLECs</t> ( n = 4). Scale bar, 200 μm in ( b ) and 1000 μm in ( c ). d – f SAR131675 inhibited the proliferation ( d ), migration ( e ), and tubule network formation ( f ) of hLECs ( n = 4). Scale bar, 200 μm in ( e ) and 1000 μm in ( f ). g Quantification of the recovered area by hLECs migration as shown in ( b ) ( n = 3). h Quantification of the recovered area by hLECs migration as shown in and ( e ) ( n = 3). i Quantification of tube lengths as shown in ( c ) ( n = 3). j Quantification of tube lengths as shown in ( f ) ( n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density ( n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. * p < 0.05; ** p < 0.01; *** p < 0.001
Human Lymphatic Endothelial Cell Line Hlecs, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lymphatic endothelial cell line hlecs/product/iCell Gene Therapeutics
Average 90 stars, based on 1 article reviews
human lymphatic endothelial cell line hlecs - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human lymphatic endothelial cells (hlec)  (iCell Bioscience Inc)
90
iCell Bioscience Inc human lymphatic endothelial cells (hlec)
Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a – c Anlotinib inhibited the proliferation ( a ), migration ( b ), and tubule network formation ( c ) of <t>hLECs</t> ( n = 4). Scale bar, 200 μm in ( b ) and 1000 μm in ( c ). d – f SAR131675 inhibited the proliferation ( d ), migration ( e ), and tubule network formation ( f ) of hLECs ( n = 4). Scale bar, 200 μm in ( e ) and 1000 μm in ( f ). g Quantification of the recovered area by hLECs migration as shown in ( b ) ( n = 3). h Quantification of the recovered area by hLECs migration as shown in and ( e ) ( n = 3). i Quantification of tube lengths as shown in ( c ) ( n = 3). j Quantification of tube lengths as shown in ( f ) ( n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density ( n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. * p < 0.05; ** p < 0.01; *** p < 0.001
Human Lymphatic Endothelial Cells (Hlec), supplied by iCell Bioscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lymphatic endothelial cells (hlec)/product/iCell Bioscience Inc
Average 90 stars, based on 1 article reviews
human lymphatic endothelial cells (hlec) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human dermal lymphatic endothelial cells (hlecs)  (Galectin Therapeutics)
90
Galectin Therapeutics human dermal lymphatic endothelial cells (hlecs)
Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a – c Anlotinib inhibited the proliferation ( a ), migration ( b ), and tubule network formation ( c ) of <t>hLECs</t> ( n = 4). Scale bar, 200 μm in ( b ) and 1000 μm in ( c ). d – f SAR131675 inhibited the proliferation ( d ), migration ( e ), and tubule network formation ( f ) of hLECs ( n = 4). Scale bar, 200 μm in ( e ) and 1000 μm in ( f ). g Quantification of the recovered area by hLECs migration as shown in ( b ) ( n = 3). h Quantification of the recovered area by hLECs migration as shown in and ( e ) ( n = 3). i Quantification of tube lengths as shown in ( c ) ( n = 3). j Quantification of tube lengths as shown in ( f ) ( n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density ( n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. * p < 0.05; ** p < 0.01; *** p < 0.001
Human Dermal Lymphatic Endothelial Cells (Hlecs), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human dermal lymphatic endothelial cells (hlecs)/product/Galectin Therapeutics
Average 90 stars, based on 1 article reviews
human dermal lymphatic endothelial cells (hlecs) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a – c Anlotinib inhibited the proliferation ( a ), migration ( b ), and tubule network formation ( c ) of hLECs ( n = 4). Scale bar, 200 μm in ( b ) and 1000 μm in ( c ). d – f SAR131675 inhibited the proliferation ( d ), migration ( e ), and tubule network formation ( f ) of hLECs ( n = 4). Scale bar, 200 μm in ( e ) and 1000 μm in ( f ). g Quantification of the recovered area by hLECs migration as shown in ( b ) ( n = 3). h Quantification of the recovered area by hLECs migration as shown in and ( e ) ( n = 3). i Quantification of tube lengths as shown in ( c ) ( n = 3). j Quantification of tube lengths as shown in ( f ) ( n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density ( n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. * p < 0.05; ** p < 0.01; *** p < 0.001

Journal: Signal Transduction and Targeted Therapy

Article Title: Anti-lymphangiogenesis for boosting drug accumulation in tumors

doi: 10.1038/s41392-024-01794-4

Figure Lengend Snippet: Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a – c Anlotinib inhibited the proliferation ( a ), migration ( b ), and tubule network formation ( c ) of hLECs ( n = 4). Scale bar, 200 μm in ( b ) and 1000 μm in ( c ). d – f SAR131675 inhibited the proliferation ( d ), migration ( e ), and tubule network formation ( f ) of hLECs ( n = 4). Scale bar, 200 μm in ( e ) and 1000 μm in ( f ). g Quantification of the recovered area by hLECs migration as shown in ( b ) ( n = 3). h Quantification of the recovered area by hLECs migration as shown in and ( e ) ( n = 3). i Quantification of tube lengths as shown in ( c ) ( n = 3). j Quantification of tube lengths as shown in ( f ) ( n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density ( n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. * p < 0.05; ** p < 0.01; *** p < 0.001

Article Snippet: The human lymphatic endothelial cell line (hLECs) was purchased from iCell, China.

Techniques: Activity Assay, In Vitro, In Vivo, Migration, Immunohistochemistry, Staining, Saline